London Daily

Focus on the big picture.
Saturday, May 31, 2025

China's fourth COVID-19 vaccine enters clinical trial stage

China's fourth COVID-19 vaccine enters clinical trial stage

China's fourth COVID-19 vaccine entered clinical trials on Tuesday in central China's Henan province. The vaccine is developed by the National Institute of Vaccines and Serums under the China National Biotechnology Group (CNBG).
This is the second inactivated COVID-19 vaccine that CNBC has developed and has been approved by the China National Administration of Medical Products for its clinical trials. The country's first inactivated COVID-19 vaccine has already entered the second phase of clinical trials on Friday.

Since the outbreak of the new coronavirus, the CNBG has allocated 1 billion yuan ($141.29 million) to develop vaccines against COVID-19 at three of its research institutes along two technical routes.

“It usually takes several years to research and develop a vaccine. But we have been working shifts throughout the day, which shortens the time. This also demonstrates the strength and speed of China, "said Wang Hui, president of the National Institute of Vaccines and Serum.

Wang said the research team has conquered a number of key technologies in vaccine production and quality control, and has conducted three clinical samples of high, moderate and low doses. The vaccine will not be released until the third phase of clinical trials is completed.

The CNBG has built the world's largest COVID-19 vaccine laboratory in Beijing, with a designed production capacity of 100 million doses each year, capable of meeting the demand for large-scale emergency use and routine vaccination. .

“It took 78 days to build the laboratory from site selection to completion of construction, while the actual construction period was only about 60 days. This is the first high-level biosafety protection laboratory for human use in China, ”said Dong Jianchun, head of the engineering support department of the National Institute of Vaccines and Serum.

"Once the laboratory is created, in accordance with the law and with the approval of the relevant state departments, the vaccine produced in it could serve special groups of people, such as medical professionals, diplomats, construction workers of the Strip and Route, and students abroad, "said Zhu Jingjin, head of the CNBG.
Newsletter

Related Articles

0:00
0:00
Close
Satirical Sketch Sparks Political Spouse Feud in South Korea
Indonesia Quarry Collapse Leaves Multiple Dead and Missing
South Korean Election Video Pulled Amid Misogyny Outcry
Asian Economies Shift Away from US Dollar Amid Trade Tensions
Netflix Investigates Allegations of On-Set Mistreatment in K-Drama Production
US Defence Chief Reaffirms Strong Ties with Singapore Amid Regional Tensions
Vietnam Faces Strategic Dilemma Over China's Mekong River Projects
Malaysia's First AI Preacher Sparks Debate on Islamic Principles
White House Press Secretary Criticizes Harvard Funding, Advocates for Vocational Training
France to Implement Nationwide Smoking Ban in Outdoor Spaces Frequented by Children
Meta and Anduril Collaborate on AI-Driven Military Augmented Reality Systems
Russia's Fossil Fuel Revenues Approach €900 Billion Since Ukraine Invasion
U.S. Justice Department Reduces American Bar Association's Role in Judicial Nominations
U.S. Department of Energy Unveils 'Doudna' Supercomputer to Advance AI Research
U.S. SEC Dismisses Lawsuit Against Binance Amid Regulatory Shift
Alcohol Industry Faces Increased Scrutiny Amid Health Concerns
Italy Faces Population Decline Amid Youth Emigration
U.S. Goods Imports Plunge Nearly 20% Amid Tariff Disruptions
OpenAI Faces Competition from Cheaper AI Rivals
Foreign Tax Provision in U.S. Budget Bill Alarms Investors
Trump Accuses China of Violating Trade Agreement
Gerry Adams Wins Libel Case Against BBC
Russia Accuses Serbia of Supplying Arms to Ukraine
EU Central Bank Pushes to Replace US Dollar with Euro as World’s Main Currency
Chinese Woman Dies After Being Forced to Visit Bank Despite Critical Illness
President Trump Grants Full Pardons to Reality TV Stars Todd and Julie Chrisley
Texas Enacts App Store Accountability Act Mandating Age Verification
U.S. Health Secretary Ends Select COVID-19 Vaccine Recommendations
Vatican Calls for Sustainable Tourism in 2025 Message
Trump Warns Putin Is 'Playing with Fire' Amid Escalating Ukraine Conflict
India and Pakistan Engage Trump-Linked Lobbyists to Influence U.S. Policy
U.S. Halts New Student Visa Interviews Amid Enhanced Security Measures
Trump Administration Cancels $100 Million in Federal Contracts with Harvard
SpaceX Starship Test Flight Ends in Failure, Mars Mission Timeline Uncertain
King Charles Affirms Canadian Sovereignty Amid U.S. Statehood Pressure
Trump Threatens 25% Tariff on iPhones Amid Dispute with Apple CEO
Putin's Helicopter Reportedly Targeted by Ukrainian Drones
Liverpool Car Ramming Incident Leaves Multiple Injured
Australia Faces Immigration Debate Following Labor Party Victory
Iranian Revolutionary Guard Founder Warns Against Trusting Regime in Nuclear Talks
Macron Dismisses Viral Video of Wife's Gesture as Playful Banter
Cleveland Clinic Study Questions Effectiveness of Recent Flu Vaccine
Netanyahu Accuses Starmer of Siding with Hamas
Junior Doctors Threaten Strike Over 4% Pay Offer
Labour MPs Urge Chancellor to Tax Wealthy Over Cutting Welfare
Publication of UK Child Poverty Strategy Delayed Until Autumn
France Detains UK Fishing Vessel Amid Post-Brexit Tensions
Calls Grow to Resume Syrian Asylum Claims in UK
Nigel Farage Pledges to Reinstate Winter Fuel Payments
Boris and Carrie Johnson Welcome Daughter Poppy
×